VX-121 Combination Therapy in Subjects With Cystic Fibrosis VX20-121-103

Conditions

Diseases of the Endocrine System | Genetics - Adult | Genetics - Pediatric

Phase III

Volunteers
Health Professionals

What is the purpose of this trial?

The purpose of this study is to evaluate the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who are homozygous for F508del, heterozygous for F508del and a gating (F/G) or residual function (F/RF) mutation, or have at least 1 other TCR CF transmembrane conductance regulator (CFTR) gene mutation and no F508del mutation.

Ages
12 years and older
Gender
Both

Find out more about who can participate in this trial

Trial with
Vertex Pharmaceuticals Incorporated
Start Date
12/16/2021
End Date
07/31/2023

For more information about this study, contact:

Catalina Guzman

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Marie Egan, MD
Professor of Pediatrics (Respiratory) and of Cellular And Molecular Physiology; Director, Cystic Fibrosis Center; Vice Chair for Research, Department of Pediatrics

Sub-Investigators

Last Updated
05/09/2022
Study HIC
#2000030926

VX-121 Combination Therapy in Subjects With Cystic Fibrosis VX20-121-103

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information